| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/10/2013 | EP2575810A1 Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| 04/10/2013 | EP2575809A1 Compositions for treating helicobacter pylori infection |
| 04/10/2013 | EP2575808A1 Combination of antihypertensive agents |
| 04/10/2013 | EP2575807A1 Formulation based on sulpiride and a synergistic homeopathic composition for treatment of depressive syndrome |
| 04/10/2013 | EP2575806A1 New compounds for the prevention and/or treatment of osteoarthrosis |
| 04/10/2013 | EP2575805A2 Methods of treatment |
| 04/10/2013 | EP2575804A1 Methods of treatment of pancreatic cancer |
| 04/10/2013 | EP2575803A1 Methods of treating bladder cancer |
| 04/10/2013 | EP2575802A1 Phosphaplatins and their use for treatment of cancers |
| 04/10/2013 | EP2575801A1 Novel iridium/rhodium anti-cancer compounds |
| 04/10/2013 | EP2575800A1 Rhenium complexes and their pharmaceutical use. |
| 04/10/2013 | EP2575799A1 Methods for treating inflammatory autoimmune disorders |
| 04/10/2013 | EP2575798A1 Gastroretentive dosage forms of gaba analogs |
| 04/10/2013 | EP2575797A1 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases |
| 04/10/2013 | EP2575796A1 Formulations comprising calcium, vitamin d and vitamin k for osteoporosis |
| 04/10/2013 | EP2575795A1 Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care |
| 04/10/2013 | EP2575794A2 Autotaxin pathway modulation and uses thereof |
| 04/10/2013 | EP2575793A1 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament |
| 04/10/2013 | EP2575792A1 Biguanide compounds and its use for treating cancer |
| 04/10/2013 | EP2575791A2 Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
| 04/10/2013 | EP2575789A1 Diversion-resistant microgranules and microtablets |
| 04/10/2013 | EP2575787A1 Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
| 04/10/2013 | EP2575785A1 Oral dosage forms of bendamustine and therapeutic use thereof |
| 04/10/2013 | EP2575784A1 Oral dosage forms of bendamustine |
| 04/10/2013 | EP2575783A2 Methods and compositions for oral pharmaceutical therapy |
| 04/10/2013 | EP2575782A2 Effervescent formulations comprising cephalosporin and clavulanic acid |
| 04/10/2013 | EP2575781A1 Production method for the effervescent formulation comprising cephalosporin and potassium clavulanate |
| 04/10/2013 | EP2575780A1 Extended release formulation of pramipexole |
| 04/10/2013 | EP2575778A1 Pharmaceutical compositions of co-crystals of tramadol and coxibs |
| 04/10/2013 | EP2575774A1 Combination therapy methods for treating proliferative diseases |
| 04/10/2013 | EP2575773A2 Synthetic nanocarrier combination vaccines |
| 04/10/2013 | EP2575766A1 Novel pharmaceutical compounds |
| 04/10/2013 | EP2575765A2 Oral spray formulations and methods for administration of sildenafil |
| 04/10/2013 | EP2575763A2 Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer |
| 04/10/2013 | EP2575760A1 Formulation comprising nicotine and a cation exchange resin |
| 04/10/2013 | EP2575759A1 Formulation comprising nicotine and a cation exchange resin |
| 04/10/2013 | EP2575758A1 Formulation for osteoporosis |
| 04/10/2013 | EP2575757A1 Water soluble formulation comprising a combination of amlodipine and a statin |
| 04/10/2013 | EP2575756A2 Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition |
| 04/10/2013 | EP2575745A1 Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope |
| 04/10/2013 | EP2575501A2 Stable high lipid liquid formula |
| 04/10/2013 | EP2575487A1 Oral formulations of bipolar trans carotenoids |
| 04/10/2013 | EP2575475A1 Inhibitors of hcv ns5a |
| 04/10/2013 | EP2575474A1 Methods for increasing the production or activity of catalase |
| 04/10/2013 | EP2575473A1 Soluble guanylate cyclase activators |
| 04/10/2013 | EP2575467A1 Macrocyclic compounds useful as inhibitors of histone deacetylases |
| 04/10/2013 | EP2575466A1 Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin |
| 04/10/2013 | EP2575465A1 Salts of raltegravir |
| 04/10/2013 | EP2575464A1 New forms of rifaximin and uses thereof |
| 04/10/2013 | EP2575463A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/10/2013 | EP2575462A1 Heterocyclic compounds and uses thereof |
| 04/10/2013 | EP2575461A1 Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators |
| 04/10/2013 | EP2575460A1 Combination |
| 04/10/2013 | EP2575459A1 Cancer treatment with wortmannin analogs |
| 04/10/2013 | EP2575458A1 Tocotrienol compositions |
| 04/10/2013 | EP2575457A1 Oral pharmaceutical composition of duloxetine |
| 04/10/2013 | EP2575455A2 Methods and compositions for treating a subject for central nervous system (cns) injury |
| 04/10/2013 | EP2575454A1 Naphthalene carboxamide m1 receptor positive allosteric modulators |
| 04/10/2013 | EP2575452A1 Antimicrobial compositions |
| 04/10/2013 | EP2356105B1 ( pyrrolidin-2 -yl) phenyl derivatives for use in the treatment of pain |
| 04/10/2013 | EP2114147B9 Reducing side effects of tramadol |
| 04/10/2013 | CN202859717U Physical antimicrobial film |
| 04/10/2013 | CN202859700U Traditional Chinese medicine decoction pieces |
| 04/10/2013 | CN202859699U Cistanche decoction piece product |
| 04/10/2013 | CN202859698U Desertliving cistanche decoction pieces |
| 04/10/2013 | CN1817846B Production of polyunsaturated fatty acids using novel cell treatment method |
| 04/10/2013 | CN1759114B Heterocyclic N-aryl carboxamides as cytokine inhibitors |
| 04/10/2013 | CN103038364A Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| 04/10/2013 | CN103038355A Procedure for the obtainment of fatty acids of pharmacological and nutritional interest |
| 04/10/2013 | CN103038349A Regulation of metabolism by miR-378 |
| 04/10/2013 | CN103038289A Naphthocyanines for use as contrast agents |
| 04/10/2013 | CN103038245A Modified c-3 betulinic acid derivatives as HIV maturation inhibitors |
| 04/10/2013 | CN103038239A Crystalline forms of kinase inhibitors |
| 04/10/2013 | CN103038238A Crystal of thienopyrimidine derivative |
| 04/10/2013 | CN103038235A Substituted imidazopyrazines |
| 04/10/2013 | CN103038234A Compounds with antibacterial activity against clostridium |
| 04/10/2013 | CN103038233A Pyridone and aza-pyridone compounds and methods of use |
| 04/10/2013 | CN103038232A The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| 04/10/2013 | CN103038231A Modulators of HEC1 activity and methods therefor |
| 04/10/2013 | CN103038230A Aminopyrimidine derivatives as LRRK2 modulators |
| 04/10/2013 | CN103038229A Heteroaryl compounds and methods of use thereof |
| 04/10/2013 | CN103038228A Substituted pyrimidines as prostaglandin D2 receptor antagonists |
| 04/10/2013 | CN103038227A Nilotinib salts and crystalline forms thereof |
| 04/10/2013 | CN103038223A Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
| 04/10/2013 | CN103038221A Chk-1 activity regulator |
| 04/10/2013 | CN103038219A Compounds acting at multiple prostaglandin receptors to give a general anti-inflammatory response |
| 04/10/2013 | CN103038218A Condensed ring pyridine compound |
| 04/10/2013 | CN103038216A Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| 04/10/2013 | CN103038211A Crystalline form of a 3-phenoxymethylpyrrolidine compound |
| 04/10/2013 | CN103038210A Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 04/10/2013 | CN103037904A 2-iminobiotin formulations and uses thereof |
| 04/10/2013 | CN103037884A Pharmaceutical or neutraceutical formulation |
| 04/10/2013 | CN103037881A Novel formulations of active ingredient(s) of plant origin or synthetic analogues thereof or of extract(s) of plant origin containing same, and of lecithin |
| 04/10/2013 | CN103037869A Method of treating inflammation |
| 04/10/2013 | CN103037867A Borinic compositions |
| 04/10/2013 | CN103037866A Fish parasite extermination agent and extermination method |
| 04/10/2013 | CN103037865A Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| 04/10/2013 | CN103037864A Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| 04/10/2013 | CN103037863A Method for treating schizophrenia and related diseases |
| 04/10/2013 | CN103037862A Methods of treating or preventing estrogen-related diseases |